Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Merck Pulls Plug On Acquired Drug after Safety Review

Merck & Co. Inc. (NYSE:MRK) on Tuesday announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and other hematologic malignancies in the BELLWAVE…

Merck Pulls Plug On Acquired Drug after Safety Review

Merck & Co. has halted the development of its investigational drug nemtabrutinib (MK-1026), a Bruton’s tyrosine kinase inhibitor. The discontinuation follows a review by an external Data Monitoring Committee (eDMC), which concluded that the potential benefits may not outweigh the risks. The decision was made after evaluating Phase 3 BELLWAVE-011 trial results.

Merck also suspended the broader BELLWAVE clinical development program, which included BELLWAVE-008 and BELLWAVE-010 trials. The company acquired nemtabrutinib through a deal with Terns Pharmaceuticals Inc. for approximately $6.7 billion. At the EHA 2023 conference, Merck shared positive Phase 1/2 results from the BELLWAVE-001 trial, which demonstrated a 32% objective response rate (ORR) and a 24.4-month median duration of response (mDOR) in patients with B-cell malignancies. Merck's stock declined 2.26% to $140.13 following the news.

Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at benzinga.com →

More in Finance & Markets

More from Wednesday 18 November →